Optimizing Bruton Kinase (BTK) Inhibitors in Relapsed/Refractory (R/R) Mantle Cell Lymphoma - Episode 6

Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

,

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Mantle Cell Lymphoma
    EP. 2: Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma
    EP. 3: Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma
    EP. 4: Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma
    EP. 5: Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma
    Now Viewing
    EP. 6: Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma
    EP. 7: Future Directions in the Treatment of Mantle Cell Lymphoma
    x